A
AeroRx Therapeutics
Nebulized combination therapies for chronic respiratory diseases
About AeroRx Therapeutics
AeroRx Therapeutics is a clinical-stage biopharmaceutical firm founded in 2022, located in La Jolla, California. The company spun off from iPharma Lab's inhalation contract development and research business. It is focused on creating proprietary, nebulized combination drug products to treat chronic respiratory diseases, particularly Chronic Obstructive Pulmonary Disease (COPD). The company's business model centers on developing these therapies through clinical trials and seeking regulatory approval to bring them to market, addressing a significant portion of the COPD population that is poorly served by existing handheld inhalers.
The co-founder and CEO, Ahmet Tutuncu, M.D., Ph.D., is a clinician and scientist with over three decades of experience in the pharmaceutical industry, focusing on respiratory and critical care. His background includes co-founding Patara Pharma and Elevation Pharma, both of which were acquired, and leading development activities for three successful NDAs/MAAs for respiratory treatments. Another co-founder is Keith Ung, who serves as the company's President.
AeroRx's lead product candidate is AERO-007, the first nebulized LABA/LAMA (long-acting beta-agonist/long-acting muscarinic antagonist) fixed-dose combination therapy in development for COPD. It combines two FDA-approved bronchodilators, indacaterol and glycopyrrolate, in a proprietary formulation delivered via a standard jet nebulizer. This approach targets patients who struggle with handheld inhalers, which can be difficult to use correctly, leading to suboptimal dosing for up to 75% of users. Nebulized delivery provides a passive-breathing alternative designed to ensure more consistent and effective dosing, especially for older adults and those with advanced COPD. In October 2025, AeroRx announced a $21 million Series A financing led by Avalon BioVentures to advance AERO-007 into late-stage clinical development, following positive Phase 2a trial data that showed the treatment was well-tolerated and provided rapid, sustained 24-hour bronchodilation. The company also has a second program, AERO-111, in development as the first potential nebulized LABA/LAMA/ICS (inhaled corticosteroid) triple therapy for patients requiring treatment escalation.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $1M | $105M | The Conrad Prebys Foundation | ↗ |
| SERIES A✓Equity / VC | Oct 2025 | $21M | $84M | Correlation Ventures · Avalon BioVentures · Alexandria Venture Investments | ↗ |
Growth signals
Latest recorded traffic for AeroRx Therapeutics is 1.3K monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AeroRx Therapeutics in the San Diego ecosystem
The AeroRx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
The Conrad Prebys Foundation
Avalon BioVentures
Correlation Ventures
Alexandria Venture Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AeroRx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AeroRx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










